Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8257399 | 0.94 | NPC1 (0.45) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL22703159 | 0.86 | NPC1 (0.45) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL828662 | 0.86 | NPC1 (0.42) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL31754779 | 0.84 | SYK (0.41) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL21999271 | 0.84 | SYK (0.41) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL24035707 | 0.83 | SYK (0.41) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL1353862 | 0.83 | SYK (0.41) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL30161746 | 0.83 | SYK (0.41) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL828561 | 0.82 | NPC1 (0.39) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL828278 | 0.82 | USP30 (0.40) | NPC1RAB9ATP53PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20210340105-A1 | AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | Cortexyme, Inc. (US) | 2021-11-04 | — | — | US | disclosed |
| US-11059786-B2 | Aminopyridine compounds and methods for the preparation and use thereof | Cortexyme, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200148642-A1 | AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | Cortexyme, Inc. (US) | 2020-05-14 | — | — | US | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1871741-A2 | SUBSTITUTED AZETIDINONES | Daiamed, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| WO-2006108039-A2 | SUBSTITUTED AZETIDINONES | DAIAMED, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006108039-A2 | SUBSTITUTED AZETIDINONES | DAIAMED, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-7019019-B2 | Matriptase inhibitors and methods of use | DENDREON CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040186060-A1 | Matriptase inhibitors and methods of use | DENDREON CORPORATION | 2004-09-23 | — | — | US | disclosed |
| WO-2004058688-A1 | MATRIPTASE INHIBITORS AND METHODS OF USE | DENDREON CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | NPC1 3423/4885RAB9A 453/4885TP53 4048/4885 |
| US-20200148642-A1 | AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | ENPEP, DNPEP, ANPEP | NPC1 4466/4885RAB9A 591/4885TP53 900/4885 |
| US-20040186060-A1 | Matriptase inhibitors and methods of use | MMP7, SPINT2, TMPRSS6 | NPC1 2737/4885RAB9A 3843/4885TP53 405/4885 |
| US-20100144698-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | NPC1 3423/4885RAB9A 453/4885TP53 4048/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | NPC1 3423/4885RAB9A 453/4885TP53 4048/4885 |
| US-11059786-B2 | Aminopyridine compounds and methods for the preparation and use thereof | ENPEP, DNPEP, ANPEP | NPC1 4466/4885RAB9A 591/4885TP53 900/4885 |
| US-20210340105-A1 | AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | ENPEP, DNPEP, ANPEP | NPC1 4466/4885RAB9A 591/4885TP53 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.